CDSCO India Medical Device Registration & Approval

India regulates medical devices and in vitro diagnostics under the Medical Devices Rules, 2017. The Central Drugs Standard Control Organisation (CDSCO), led by the Drugs Controller General of India, handles central functions such as import licensing and higher-risk device oversight, while State Licensing Authorities perform specified functions for lower-risk domestic devices. CDSCO maintains the official medical devices and diagnostics portal.

India medical device classification

All medical devices are regulated under the risk-based framework and classified as Class A, B, C, or D. Class A is the lowest risk and Class D the highest. Classification depends on intended use, duration, invasiveness, active functions, and the potential harm from an incorrect result or failure. The applicable authority, form, evidence, inspection pathway, and fee depend on whether the product is imported or manufactured in India and on its class.

Import license and Indian Authorized Agent

An overseas manufacturer generally appoints an Indian Authorized Agent that holds the appropriate wholesale or manufacturing license and is authorized to submit and maintain the import application. The agent files Form MD-14 for an import license; an approved license is issued in Form MD-15. The application can cover defined sites and device groups, so product grouping and site strategy should be planned before filing.

The agency agreement should address control and access to the dossier, responses to CDSCO, renewals and retention fees, change reporting, complaint handling, vigilance, recalls, and transfer arrangements. A local commercial distributor is not automatically the same as the regulatory agent unless it holds the appropriate authorization and accepts those responsibilities.

Evidence and lifecycle

A typical import dossier includes manufacturer and site information, quality-management-system evidence, intended use and classification, a device master file, plant master file, labeling, authorization documents, free-sale or market-authorization evidence where applicable, and technical, clinical, or performance data proportionate to risk. CDSCO may inspect a manufacturing site or request additional evidence depending on the route and product history.

After licensing, the manufacturer and agent must maintain current site and product details, approved labels, quality certificates, import records, complaint procedures, adverse-event reporting, and recall readiness. Design, software, intended-use, site, or labeling changes should be assessed before implementation to determine whether CDSCO approval, notification, or license amendment is required.